ClinicalTrials.gg
RecruitingNCT06453317COMBO-UCUpdated May 15, 2025

Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis

A Phase 2 interventional study of Infliximab and Ustekinumab in Ulcerative Colitis and Inflammatory Bowel Diseases, sponsored by Medical University of Lodz. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Medical University of Lodz · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing infliximab in Colitis, Ulcerative — 7 open to participants now, 9 under way, 2 of them phase 3. Infliximab · Colitis, Ulcerative.

Planned enrollment
6th of 26
172 · median 78
Started
2025
with 1 other
Phase 2
2 of 26
2 open now
Registered
23rd of 26
by date

Among the 26 studies testing infliximab in Colitis, Ulcerative, this one is the 6th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 2, and was the 23rd registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

7 of the 26 studies testing infliximab in Colitis, Ulcerative are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing infliximab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if combined therapy with infliximab and ustekinumab works better than using these drugs alone in adult patients with ulcerative colitis. It will also learn about the safety of this combination. The main questions it aims to answer are:

Does the combination therapy improve the symptoms and heal the intestine quicker and better than these drugs administered alone? Does the combination therapy improve the quality of life better than these drugs administered alone? What medical problems do participants have when taking the combination therapy?

Participants:

Patients diagnosed with UC will be qualified to biologic therapy (infliximab/ustekinumab/infliximab + ustekinumab).

Visit the clinic in stated periods for assessment and to apply medication. Take drugs based on the schedule.

03

Conditions studied

  • Ulcerative Colitis
  • Inflammatory Bowel Diseases

Keywords

  • dual biological therapy
  • infliximab
  • ustekinumab
  • Inflammatory Bowel Diseases
  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Obtaining informed, written consent for the patient's participation in the in the study and for all planned procedures.
  2. Age ≥ 18 years and ≤65 at the time of screening.
  3. In the case of women of , agreement to not donate oocytes for the entire period of participation in the in the study and 6 months after receiving the last dose of the drug.
  4. For women of reproductive potential, agreement to use effective (Table 4) during the entire period, during which the patient participates in the study and for a period counted from the last dose of 15 weeks if using UST (patients in arms B and C) or 6 months if using IFX (patients in arm A).
  5. Negative serum or urine pregnancy test in women of childbearing age.
  6. Diagnosis of UC a minimum of. 3 months prior to screening documented by:

    (a) medical source documentation of the patient with the result of an endoscopic examination that diagnosed features typical of UC.

    (b) a histopathological examination result consistent with UC. In the absence of a histopathological result, it is possible to take sections during the endoscopic examination for histopathological evaluation at the time of eligibility for the study with subsequent sending of the material to the local pathomorphology laboratory to confirm the diagnosis of UC before randomization.

  7. UC with moderate or severe activity defined as a Mayo scale score (Appendix 2) of 7 to 12 including the following sub-item values (each sub-item 0-3 points depending on the severity of the lesions):

    - Frequency of bowel movements

    • Bowel bleeding
    • Endoscopic image of the colonic mucosa
    • General medical evaluation and:
    • with inadequate response to standard treatment, including and 6-mercaptopurine or azathioprine, or.
    • intolerant of treatment with corticosteroids and 6-mercaptopurine or azathioprine, or
    • having to treatment with corticosteroids and 6-mercaptopurine or azathioprine, or
    • with loss of response to standard treatment, including to treatment with corticosteroids and 6-mercaptopurine or azathioprine, including patients:
    • Steroid-resistant - in whom there is no clinical improvement despite the use of a daily steroid up to 0.75 mg/kg prednisolone for 4 weeks;
    • Steroid-dependent - in whom failure to reduce the steroid dose below 10 mg/day, converted to prednisolone, within 3 months of starting steroid therapy or relapse of complaints within 3 months of steroid withdrawal.
    • patients/about inadequate response to treatment, defined as lack of remission or recurrence of complaints despite immunosuppressive treatment for at least 3 months at appropriate doses (azathioprine 2-2.5 mg/kg/day or 6-mercaptopurine 1-1.5 mg/kg/day).
  8. Patients taking 5-ASA derivatives, corticosteroids, immunosuppressants may be included in the study if they are taking a fixed and specified dose of the above drugs 14 days before the day of randomization.

Exclusion criteria

Exclusion Criteria:

  1. Previous use of the study drug IFX or UST.
  2. to the active substance or .
  3. Moderate or severe myocardial insufficiency ( III or IV).
  4. Unstable coronary artery disease.
  5. History of serious cerebrovascular disease (stroke, intracranial hemorrhage, transient cerebral ischemia) within the last 24 weeks prior to screening.
  6. Chronic respiratory failure.
  7. Severe chronic renal failure.
  8. Severe chronic liver failure.
  9. Demyelinating syndrome or symptoms resembling the syndrome.
  10. Alcoholic disease, post-alcoholic liver damage.
  11. Diagnosis of malignant neoplasms, including within 5 years preceding the time of eligibility for the program (except for carcinoma in situ of the cervix, and non-melanoma skin cancers).

12 Complications requiring other management (e.g., surgery). 13. Current or recent (defined as an incident within 12 weeks prior to randomization) documented episode of fulminant colitis, or intra-abdominal abscess, or acute colonic distension, or bowel perforation.

14. Status after extensive colorectal resection, subtotal or total colectomy with or without colostomy, or J-pouch reservoir.

15. Indication of surgical intervention due to underlying disease or when there is a suspicion of need for such intervention during the course of the study.

16. History of current or previously documented unclassified colitis or ischemic colitis.

17. History of colonic diverticulitis within the last 60 days prior to the randomization visit.

18. Current adenomatous polyps of the colon, small- or large-grade dysplasia in colon specimens, or previously diagnosed foci of large-grade dysplasia that have not been treated.

19. Enteral nutrition or total parenteral nutrition. 20. Pregnancy or breastfeeding. 21. Taking medications on the prohibited drugs list (Section 7.4.6). 22. daily dose of prednisone> 40 mg (or equivalent other ) or budesonide MMX > 9 mg.

23. Status after bone marrow transplantation. 24. Condition after apheresis 12 months prior to the randomization visit. 25. Period after administration of allowed biologic drugs shorter than the drug's from the body (Section 7.2).

26. Period after intestinal microbiota transplantation less than 8 weeks before signing to participate in the study.

27. Active or latent form of tuberculosis. 28. infection. 29. Treatment period for active lesions of chronic infections (including pneumocystodosis, CMV, HPV, HSV infection, atypical mycobacteriosis, invasive bacterial or fungal infections).

30 History of HSV, HPV, influenza virus, SARS-CoV2 infection within 12 weeks prior to randomization or history of disseminated or complicated HSV infection.

31. History of congenital or acquired immunodeficiency. 32. receipt of within 30 days prior to randomization. 33. infection with or . 34. changes on chest X-ray or . 35 Clinically significant changes observed in laboratory test results:

  1. activity >3x the (GGN)
  2. AST activity >3x GGN
  3. Total level >2x GGN (exception is Gilbert syndrome when other causes of isolated hyperbilirubinemia are excluded).
  4. ALP or GGTP activity >3x GGN
  5. Creatinine level >2x GGN or impaired renal function () \<45mL/min calculated by MDRD formula.
  6. level \<9g/dL
  7. Absolute leukocyte count \<3000/mm3
  8. Absolute lymphocyte count \<750/mm3
  9. Neutrophil level \<1000/mm3
  10. level \<100000/mm3. 36. Positive stool culture for bacteria/fungus (if clinically relevant in the opinion of the investigator).

    37.Positive stool culture for Clostridioides difficile. 38. Use of treatment not permitted under this protocol.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
172 participants (estimated)

Study arms

  • Active comparator
    Infliximab

    Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.

    Biological: Infliximab

  • Active comparator
    Ustekinumab

    Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.

    Biological: Ustekinumab

  • Experimental
    Infliximab + Ustekinumab

    Infliximab 5 mg/kg i.v. at Week 0, 2, 6. \+ Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks

    Biological: Infliximab · Biological: Ustekinumab

Interventions

  • BiologicalInfliximab

    Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.

  • BiologicalUstekinumab

    Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of patients with clinical and endoscopic remission after the induction phase.

    Clinical remission: PRO-2 score ≤1 points, total Mayo score \<3 Endoscopic remission: endoscopic Mayo score ≤1

    Time frame: Week 14 for Infliximab arm and Week 16 for Ustekinumab and Infliximab + Ustekinumab arms

Secondary outcomes

  1. Percentage of patients with clinical response after the induction phase.

    Clinical response: change in PRO-2 score ≥50% or a change in total Mayo score ≥3 points

    Time frame: Week 14 for Infliximab arm and Week 16 for Ustekinumab and Infliximab + Ustekinumab arms

  2. Percentage of patients with clinical response at Week 52.

    Clinical response: change in PRO-2 score ≥50% or a change in total Mayo score ≥3 points

    Time frame: Week 52

  3. Percentage of patients with clinical remission at Week 52.

    Clinical remission: PRO-2 score ≤1 points, total Mayo score \<3

    Time frame: Week 52

  4. Percentage of patients with endoscopic response or remission after the induction phase and at Week 52

    Endoscopic response: change in endoscopic Mayo score ≥1 point Endoscopic remission: endoscopic Mayo score ≤1

    Time frame: Week 14 for Infliximab arm and Week 16 for Ustekinumab and Infliximab + Ustekinumab arms and Week 52

  5. Percentage of patients with biochemical remission after the induction phase and at Week 52.

    Biochemical remission: calprotectin level ≤125 µg/g of stool

    Time frame: Week 14 for Infliximab arm and Week 16 for Ustekinumab and Infliximab + Ustekinumab arms and Week 52

  6. Percentage of patients with histological remission after the induction phase.

    Deep remission: PRO-2 score = 0 points, endoscopic Mayo score = 0 points and Picasso Histologic Remission Index = 0 points

    Time frame: Week 14 for Infliximab arm and Week 16 for Ustekinumab and Infliximab + Ustekinumab arms

  7. Comparison of patients' quality of life after the induction phase and at Week 52 using 36-Item Short Form Survey (SF-36) and Inflammatory Bowel Disease Questionnaire (IBDQ).

    SF-36: 0-100 points (a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). IBDQ: 32-224 points (higher scores representing better quality of life).

    Time frame: Week 14 for Infliximab arm and Week 16 for Ustekinumab and Infliximab + Ustekinumab arms and Week 52

  8. Comparison of incidence of treatment-emergent adverse events after the induction phase and at Week 52.

    Treatment-emergent adverse events and serious adverse events will be assessed

    Time frame: Week 14 for Infliximab arm and Week 16 for Ustekinumab and Infliximab + Ustekinumab arms and Week 52

07

Study locations

1 of 1 sites recruiting
  • Oddział Kliniczny Gastroenterologii Ogólnej i Onkologicznej USK nr 1 im. N. Barlickiego w Łodzi
    Lodz, 90-153, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Apr 2028, 38 months after the start.

Of 45 non-industry phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 38 months is below that.

Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
Jun 11, 2024
StartActual
Feb 17, 2025
Primary completionEst.
Apr 30, 2028
CompletionEst.
Jun 30, 2028
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06453317
Collaborators
Poznan University of Medical Sciences, Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań, Norbert Barlicki Memorial Teaching Hospital No. 1 of the Medical University of Lodz, Medical Research Agency, Poland
Responsible party
Renata Talar-Wojnarowska (Principal Investigator, Medical University of Lodz) — Principal investigator
First posted
Jun 11, 2024
Start date
Feb 17, 2025
Primary completion
Apr 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
May 15, 2025

Study contacts

Renata Talar-Wojnarowska, Prof.
Contact
renata.talar-wojnarowska@umed.lodz.pl
+48426776664
Adam Fabisiak, PhD, MD
Contact
adam.fabisiak@umed.lodz.pl
+48500316396
Renata Talar-Wojnarowska, Prof.
principal investigator · Medical University of Lodz

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Infliximab · Ustekinumab

Start the discussion